Navegando por Palavras-chave "vancomycin resistance"

Agora exibindo 1 - 3 de 3
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    Endocarditis due to glycopeptide-intermediate Staphylococcus aureus: case report and strain characterization
    (Elsevier B.V., 2003-02-01) Andrade-Baiocchi, S.; Tognim, MCB; Baiocchi, Otavio Carvalho Guimarães [UNIFESP]; Sader, H. S.; Universidade Federal de São Paulo (UNIFESP)
    We report a case of infective endocarditis due to vancomycin-intermediate Staphylococcus aureus (VISA) that did not respond to high doses of vancomycin. Initial vancomycin MIC of the last isolate recovered from blood was 8 1 mug/mL, but could be induced up to 32 mug/mL by consecutive growing with vancomycin. Clinical response was only accomplished when linezolid was included in therapy. (C) 2003 Elsevier Science Inc. All rights reserved.
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    In vitro activity of omiganan pentahydrochloride tested against vancomycin-tolerant, -intermediate, and -resistant Staphylococcus aureus
    (Elsevier B.V., 2008-04-01) Fritsche, Thomas R.; Rhomberg, Paul R.; Sader, Hello S. [UNIFESP]; Jones, Ronald N.; JMI Labs; Universidade Federal de São Paulo (UNIFESP)
    Omiganan, a novel topical cationic peptide active against a broad spectrum of bacteria and yeast, is targeted for the prevention of catheter-associated infections. the spectrum of this agent was evaluated against contemporary methicillin-(oxacillin)-resistant Staphylococcus aureus (MRSA; 109 isolates), including subgroups displaying reduced susceptibility to vancomycin. Strain phenotypes included: vancomycin-tolerant (MBC/MIC ratio, >= 32-fold);vancomycin-intermediate (VISA; MIC values, 4-8 pg/ml); heterogeneous vancomycin-intermediate (hVISA); and vancomycin-resistant (VRSA; MIC values, >= 16 pg/ml) S. aureus. All S. aureus tested were inhibited by <= 64 mu g/ml of omiganan, with MIC50/MTC90 values of 16/32 mu g/ml, respectively. Compared to wild-type S. aureus, MIC90 values were only 2-fold greater for vancomycin-tolerant, hVISA and VISA strains. the VRSA isolates, representing the most resistant strains tested, were inhibited by 16 mu g/ml (mode for all groups). Omiganan demonstrated potent activity against S. aureus, regardless of harbored resistance mechanism. Given the worrisome emergence of S. aureus with reduced susceptibility to vancomycin, the demonstration that omiganan remains equally active against all isolates of this species at a level significantly below the clinical formulation concentration (1% gel; 10,000 mu g/ml) is an important attribute. (C) 2008 Elsevier Inc. All rights reserved.
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    Update of the in vitro activity of daptomycin tested against 6710 Gram-positive cocci isolated in North America (2006)
    (Elsevier B.V., 2008-06-01) Castanheira, Mariana; Jones, Ronald N.; Sader, Helio S. [UNIFESP]; JMI Labs; Tufts Univ; Universidade Federal de São Paulo (UNIFESP)
    Gram-positive bacterial strains (6710) consecutively collected during 2006 in hospitals located in the United States and Canada were tested by reference broth microdilution methods against daptomycin and comparison agents. Only 1 Staphylococcus aureus strain (0.01%) had nonsusceptible daptomycin MIC value as specified by published break points. S. aureus daptomycin MIC distributions from 2006 as compared with those of previous years did not show MIC creep. Resistance to other compounds, such as vancomycin, oxacillin and penicillin, did not adversely influence daptomycin activity. Daptomycin remains highly active against clinical Gram-positive isolates collected in North America. (C) 2008 Elsevier Inc. All rights reserved.